An interventional study of Bespoke Decision Support tool and Standard of Care (SOC) decision support material in Localised Prostate Cancer, sponsored by University College, London. Recruiting at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2026-07-29.
Sponsored by University College, London · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Prostatic Neoplasms by University College, London — 9 open to participants now, 17 under way, 3 of them phase 3. Prostatic Neoplasms · University College, London.
Among the 32 studies in Prostatic Neoplasms by University College, London, this one is the 14th largest by planned enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2026, is one of 10 with no phase, reaches primary completion later than 8 of the 16 other live ones, and was the 29th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →9 of the 32 studies in Prostatic Neoplasms by University College, London are open now, in 1 country. Recruiting first, the newest first:
University College, London · Sites in United Kingdom
Ages 18+ · Men only
University College, London · Sites in United Kingdom
Ages 18+ · Men only
University College, London · Sites in United Kingdom
Ages 18+ · Men only
University College, London · Sites in United Kingdom
Ages 18+ · Men only
University College, London · Sites in United Kingdom
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 6
First in 2006; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 346 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 454 across the 20 interventional studies, 300 across the 12 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University College, London is the lead sponsor of 652 studies on the registry; 149 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
1 of the studies in Prostatic Neoplasms by University College, London that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07135271University College, LondonBeSpoke Decision Support for Patients With Newly Diagnosed Localised Prostate Cancer | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies in Prostatic Neoplasms by University College, London, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this randomised clinical trial is to assess whether personalised treatment counselling can improve the decision-making experience in patients with a new diagnosis of localised prostate cancer. The main question it aims to answer is:
Researchers will compare the addition of the Bespoke Decision Support tool to standard treatment counselling versus standard counselling alone.
Patient participants will:
Health Care Professional participants will:
Recruited patient participants will be randomised into two arms:
The standard of care (SOC) arm includes the nationally-approved Prostate Cancer UK booklet "Prostate Cancer - A guide if you have recently been diagnosed" and patient appointments to discuss different treatments with clinicians, as per local practice that offer them. Further educational material may be provided as per local practice at each site.
The intervention arm will offer additional BeSpoke Decision Support providing:
All participants will complete questionnaires on demographic data, functional status and measures of decision-making experiences at several time points: enrolment (prior to treatment discussion consultation); after treatment decision has taken place; at 3, 6, and 12 months after treatment commences.
The investigators will interview health care professionals and a sample of patient participants to assess the effect of the BeSpoke Decision Support and the challenges in implementation across the NHS.
Inclusion Criteria for Patient-Participants:
Clinically suitable for at least two of the following treatment options:
Exclusion Criteria for Patient Participants:
Suspicion of prostate cancer based on clinical or imaging evidence including:
Inclusion criteria for Health Care Professionals:
Exclusion criteria for Health Care Professionals
1. No experience of BeSpoke Decision Support.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard of Care Counselling information
Other: Standard of Care (SOC) decision support material
Standard of care counselling plus access to BeSpoke Decision Support tool
Other: Bespoke Decision Support tool · Other: Standard of Care (SOC) decision support material
A newly-developed online patient decision aid offering comparative information of prostate cancer treatments (active surveillance, focal therapy, radical prostatectomy and external beam radiotherapy), personalised estimates of oncological and functional outcomes for each treatment and a value-clarification exercise.
Standard of care information to inform the prostate cancer treatment decision. This includes the nationally approved Prostate Cancer UK information booklet "Prostate Cancer - A guide if you have just been diagnosed" in all sites. Further educational material may be provided as part of standard of care depending on local practice at each site.
Decisional Conflict Scale (DCS)
Mean difference in DCS between control (SOC) arm and intervention (Bespoke Decision Support) groups. Scores range from 0 \[no decisional conflict\] to 100 \[extremely high decisional conflict\].
Time frame: After treatment decision is confirmed, assessed as patient-reported outcome measure via questionnaire delivered on average after 4 weeks from enrolment.
Preparation for Decision Making (PrepDM) Scale
Mean difference in PrepDM Scale between control and intervention group. Scores range from 0 to 100 \[higher scores indicate higher perceived level of preparation for decision making\].
Time frame: After treatment decision is confirmed, assessed as patient-reported outcome measure via questionnaire delivered on average after 4 weeks from enrolment.
Decision Self Efficacy (DSE) Scale
Mean difference in the DSE score between the control and the intervention groups. Scores range from 0 \[not at all confident\] to 100 \[very confident\].
Time frame: After treatment decision is confirmed, assessed as patient-reported outcome measure via questionnaire delivered on average after 4 weeks from enrolment.
Satisfaction With Decision (SWD) Scale
Mean difference in the SWD score between the control and the intervention groups. Scores range from 1 to 5 (5=higher satisfaction).
Time frame: Measured at multiple time points: after treatment decision is confirmed (assessed as patient-reported outcome measure via questionnaire delivered on average after 4 weeks from enrolment); and at 3, 6 and 12 months from the treatment date.
Decision Regret Scale (DRS)
Mean difference in the DRS score between the control and the intervention groups. Scores range from 0 \[no regret\] to 100 \[high regret\].
Time frame: Measured at multiple time points: after treatment decision is confirmed (assessed as patient-reported outcome measure via questionnaire delivered on average after 4 weeks from enrolment); and at 3, 6 and 12 months from the treatment date.
Satisfaction with Cancer Information Profile (SCIP) Scale
Mean difference in the SCIP score between the control and the intervention groups at time-point 1 and time-point 4. Scores for the sub-scale "Satisfaction with the amount and content of information" range from 1 to 14 (14=higher satisfaction). Scores for the sub-scale "Satisfaction with the form and timing of information" range from 7 (lower satisfaction) to 35 (higher satisfaction).
Time frame: Measured after treatment decision is confirmed (assessed as patient-reported outcome measure via questionnaire delivered on average after 4 weeks from enrolment) and at 12 months after treatment initiation.
Control Preference Scale (CPS)
Frequencies and proportion of the CPS categories in both the intervention and the control group.
Time frame: Measured at enrolment and after treatment decision is confirmed (assessed as patient-reported outcome measure via questionnaire delivered on average after 4 weeks from enrolment).
Hospital Anxiety and Depression Scale (HADS)
Frequencies and proportion of the HADS categories in both the intervention and the control group. Scores range from 0 to 21: 0-7 = Normal; 8-10 = Borderline abnormal (borderline case); 11-21 = Abnormal (case).
Time frame: Measured before giving intervention, and after 3, 6 and 12 months from treatment initiation.
Decisional Conflict Scale (DCS) Subscales
Means or medians of the intervention and the control groups for the different DCS sub-scores: * Informed sub-score (Scores range from 0 \[feels extremely informed\] to 100 \[feels extremely uninformed\]); * Values Clarity sub-score(Scores range from 0 \[feels extremely clear about personal values for benefits \& risk/side effects\] to 100 \[feels extremely unclear about personal values\]); * Support sub-score (Scores range from 0 \[ feels extremely supported in decision making\] to 100 \[feels extremely unsupported in decision making\]); * Uncertainty sub-score (Scores range from 0 \[feels extremely certain about best choice\] to 100 \[feels extremely uncertain about best choice\]); * Effective Decision sub-score (Scores range from 0 \[good decision\] to 100 \[bad decision\]).
Time frame: After treatment decision is confirmed, assessed as patient-reported outcome measure via questionnaire delivered on average after 4 weeks from enrolment.
Qualitative Assessment with Patients
Qualitative interview evaluating patient experience in treatment decision making and feedback on decision support material
Time frame: Between treatment decision being recorded and end of study (12 months after treatment initiation)
Qualitative assessment with Health Care Professionals (HCP)
Qualitative interviews with HCP (urologists, clinical oncologists, clinical nurse specialists, GPs) involved in the treatment decision making pathway of patients with prostate cancer, to inquire regarding the decision support material provided as standard of care and in the intervention arm.
Time frame: Through study completion, an average of 1 year
Number of treatment counselling consultations
Mean or median difference in number of treatment counselling consultations taking place between enrolment and treatment decision between the control and intervention group.
Time frame: From date of randomisation until the date of first documented recording of treatment decision, assessed up to 12 months.
Treatment choice
Proportion of different treatments chosen (active surveillance, focal therapy, radical prostatectomy and radiotherapy) between the intervention and the control groups.
Time frame: From date of randomisation until the date of first documented recording of treatment decision, assessed up to 12 months.
Time to treatment decision
Time passed between enrolment and recording of treatment decision between the control and intervention group.
Time frame: From date of randomisation until the date of first documented recording of treatment decision, assessed up to 12 months.
Plan to share: No — Any request to share IPD from other researchers will be evaluated by the Trial Steering Committee on an ad hoc basis.
Started Jul 2026 (actual). Primary completion is estimated for Nov 2027, 16 months after the start.
Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 16 months is below that.
Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.